Equities

Novacyt SA

NCYT:LSE

Novacyt SA

Health CareMedical Equipment and Services
  • Price (GBX)63.50
  • Today's Change-1.50 / -2.31%
  • Shares traded98.91k
  • 1 Year change51.46%
  • Beta--
Data delayed at least 20 minutes, as of May 15 2024 16:29 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Income statement information is not available for Novacyt SA.
Gross margin43.21%
Net profit margin-321.40%
Operating margin-293.16%
Return on assets-16.96%
Return on equity-21.08%
Return on investment-20.71%
More ▼

Cash flow in GBPView more

In 2022, cash reserves at Novacyt SA fell by 14.77m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 13.73m for operations while cash used for investing totalled 577.00k.
Cash flow per share-0.3173
Price/Cash flow per share--
Book value per share1.77
Tangible book value per share1.62
More ▼

Balance sheet in GBPView more

Novacyt SA appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio5.09
Quick ratio4.98
Total debt/total equity0.0036
Total debt/total capital0.0036
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.